Milestone expands access to advanced heart failure treatment and advances development of NCH’s heart transplant program
Naples, Fla. – November 19, 2026 – Naples Comprehensive Health (NCH) has become the first health system in Southwest Florida to receive approval from the Centers for Medicare & Medicaid Services (CMS) for its left ventricular assist device (LVAD) program at the NCH Rooney Heart Institute. As the first program in the region to achieve this important designation, NCH is taking a significant step forward in expanding access to advanced, life-saving heart failure therapies for our community.
An LVAD is a surgically implanted mechanical pump that helps a weakened heart circulate blood throughout the body. For eligible patients with advanced heart failure, the device can provide support while they await a heart transplant or serve as a long-term treatment when transplantation is not an option.
CMS approval follows NCH’s credentialing through DNV’s Ventricular Assist Device Facility Credentialing Program. DNV is an independent health care accrediting and certification organization that evaluates whether a program meets CMS requirements for its multidisciplinary team, patient selection and delivery of care. NCH’s LVAD program encompasses evaluation, implant surgery and ongoing management, including education and support for patients and caregivers.
The LVAD program is a key component of NCH’s broader effort to build a comprehensive advanced heart failure and transplant program. It strengthens the clinical expertise, coordinated care and long-term patient support essential to treating people with the most complex heart conditions as development of heart transplantation services continues.
“This milestone brings us another step forward in building the full spectrum of advanced heart failure care at NCH, from diagnosis and medical management to mechanical circulatory support and, ultimately, heart transplantation,” said Robert J. Cubeddu, MD, President and Brynne and Bob Coletti Endowed Chair of the NCH Rooney Heart Institute. “An LVAD program is an essential part of that continuum, allowing us to offer more options tailored to each patient’s condition and goals.”
For Southwest Florida patients and families, access to an LVAD program in the region will help reduce the burden of traveling for specialized treatment and the extensive follow-up care these devices require.
“NCH is committed to bringing medical firsts to Naples and expanding access to care that makes a meaningful difference in people’s lives,” said Paul Hiltz, President and CEO of NCH. “Becoming Southwest Florida’s first CMS-approved LVAD program delivers on that commitment while advancing our vision for heart transplantation here in our community. We are building a future in which more patients can receive even the most complex care right here in Southwest Florida.”